Pharmacological activation of GPR120 ameliorates diabetic periodontitis in mouse models through suppression of NET-associated responses.

Researchers identified GPR120, a cell-surface receptor, as a potential therapeutic target for diabetic periodontitis by showing that activating it reduced bone loss and suppressed inflammation-related responses in diabetic mice with induced gum disease.

A plain-English summary of the study's own findings — we don't add our own claims or interpretation. Read the full paper for the complete methods and results, and apply your own clinical judgement.